Tempus AI reports $411.5 million of third-quarter revenue, up 23%, and raises its 2026 forecast
Oncology test volume grew 32%, minimal residual disease tests rose about 300% to roughly 12,000 and data and apps revenue climbed 33%; full-year revenue guidance is now $1.60 to $1.605 billion.